(BPT) - On a Friday night in 1999, Al saw a TV commercial about a new cancer treatment that was enrolling patients in a clinical trial — a novel, targeted therapy that scientists were investigating for the treatment of chronic myeloid leukemia (CML), a cancer that develops in the blood-forming cells of the bone marrow.
Two years prior, Al had been diagnosed with CML. At that time, his treatment options were limited. Most people with this diagnosis faced a five-year survival rate below 40%.
Al called his doctor the following Monday to find out if the new treatment — a tyrosine kinase inhibitor (TKI) — might be right for him. He was accepted into the trial a few months later — an impactful step that is indicative of the future of Al’s treatment journey, and the bravery he continually displayed through every high and low.
A Long and Winding Road
The clinical trial Al enrolled in led to the FDA approval of the first TKI for the treatment of CML, and the first-ever targeted therapy acting on specific cancer cells while causing less damage to normal cells.
With the introduction of TKIs, the five-year survival rate for patients diagnosed with CML improved, increasing to over 70%, bringing the lifespan of a patient with CML closer to the lifespan of a person without cancer.
However, despite the significant positive impact on the treatment of CML, it is not uncommon for some patients to not respond to certain TKIs, or struggle with side effects, or find that their response or tolerability to a specific TKI changes over time.
After the clinical trial was complete, Al decided to stay on the treatment. However, while the treatment was easy to tolerate — giving him few side effects — Al’s doctors told him that his CML was not responding as well as it should have been and there was a risk that his CML would progress and become more severe.
Al participated in more clinical trials before finding a treatment that was right for him in his fourth trial. This treatment was for a different type of TKI known as Scemblix® (asciminib) tablets. Scemblix is approved by the FDA for adults with Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP) who have previously been treated with two or more TKIs1. More information about Scemblix can be found at us.scemblix.com.
Scemblix targets CML differently than other TKIs. Because cancer can mutate when it gets accustomed to how a treatment works, approaching it in a new way can outsmart the mutations. Scemblix may help patients overcome the resistance and side effects patients with CML may experience with other TKIs.
In a clinical trial, Scemblix showed how well it works to counteract cancer compared with Bosulif® (bosutinib), another TKI, in patients who had previously tried two or more TKIs1. Nearly twice as many patients on Scemblix achieved major molecular response, or MMR (25% for Scemblix [40 of 157] vs. 13% for Bosulif [10 of 75]) at 24 weeks, which is an important treatment milestone in CML, meaning that there is a low amount of the BCR::ABL in blood cells1.
This efficacy trend continued at 96 weeks, almost two years after the trial started, when more patients on Scemblix achieved MMR compared to those on Bosulif (38% [59 of 157] vs. 16% [12 of 76])1.
Additionally, in this trial [one study for 3L CML], three times fewer patients treated with Scemblix needed to stop treatment due to side effects compared to those taking Bosulif (8% for Scemblix vs. 26% for Bosulif) at the Week 96 analysis1. The most common adverse reactions in patients who received Scemblix in this trial were upper respiratory tract infections, musculoskeletal pain, headache, and fatigue1.
Al’s journey to the right treatment was made possible not only by his bravery in trying new treatment options, but also by good communication with his doctor. While Scemblix may not be right for everybody, it helped Al achieve his milestones.
Want to learn more about Al’s story and Scemblix? Visit us.scemblix.com.
APPROVED USES for SCEMBLIX® (asciminib) Tablets
SCEMBLIX is a prescription medicine used to treat adults with:
It is not known if SCEMBLIX is safe and effective in children.
IMPORTANT SAFETY INFORMATION for SCEMBLIX® (asciminib) Tablets
Before taking SCEMBLIX, tell your doctor about all your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. SCEMBLIX and other medicines may affect each other and cause side effects.
SCEMBLIX may cause serious side effects, including:
The most common side effects of SCEMBLIX include:
Your doctor may change your dose, temporarily stop, or permanently stop treatment with SCEMBLIX if you have certain side effects.
SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your doctor if this is a concern for you.
These are not all the possible side effects of SCEMBLIX. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see accompanying full Prescribing Information, including Patient Information.
1. Scemblix [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.